Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€23.11

€23.11

-0.990%
-0.23
-0.990%
-
 
08.06.26 / Stuttgart Stock Exchange WKN: A2DG49 / Name: KalVista / Stock / Pharmaceuticals / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Financial data and news for KalVista

sharewise wants to provide you with the best news and tools for KalVista, so we directly link to the best financial data sources.

News

DRI Healthcare Trust Q1 Earnings Call Highlights
DRI Healthcare Trust Q1 Earnings Call Highlights

DRI Healthcare Trust (TSE:DHT.UN) reported higher first-quarter income and expanded margins as management said the royalty investment company continued to benefit from its post-internalization cost

KalVista's (KALV) Chief Development Officer Sells 33,800 Shares for $905,000: https://cdn.content.foolcdn.com/images/1umn9qeh/production/7c4db55a3ec93213c3928bb0037d6c8d15157943-1401x1251.png?w=800&q=75&fit=max&auto=format
KalVista's (KALV) Chief Development Officer Sells 33,800 Shares for $905,000

Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals (NASDAQ:KALV), reported the exercise of 33,800 options into common stock and the immediate sale of those shares for a total

Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement: https://cdn.content.foolcdn.com/images/1umn9qeh/production/92689007d48a7203bf004166ebdb7fbc353a61ab-300x180.png?w=800&q=75&fit=max&auto=format
Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement

KalVista Pharmaceuticals (NASDAQ:KALV), a developer of oral therapies for rare diseases, closed Wednesday at $26.67, up 38.62%. The stock moved higher after news that Italy’s Chiesi Group will